From July 19, 2024 until July 20, 2024
La München - Holiday Inn München - Centru oraș, Bavaria, Germania
Postat de Canton Fair Net
https://www.esmo.org/meeting-calendar/esmo-congress-2023
Categorii: Asistență medicală și farmaceutică
Hit-uri: 1825
Datopotamab deruxtecan achieved the PFS endpoint for previously treated NSCLC. 177Lu PSMA-617 increases rPFS for metastatic castration resistant prostate cancer that is taxane-naive. Amivantamab combinations therapies are emerging as new options for EGFR mutated advanced NSCLC. Antibody-drug combinations improve outcomes for patients who have metastatic or inoperable breast cancer. Digital health technologies are revolutionising cancer care.
Utilizați o versiune mai veche a browserului dvs. web, așa că este posibil ca unele funcții să nu se afișeze corect.
Cerințe MINIMALE: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15-18, Apple Safari 7, SeaMonkey 2.15-2.23.
Meeting Resources19 Oct 2023OncologyPRO now offers meeting resources: +3.000 slides and webcasts; abstracts and ePosters.Access to resources.
OncologyPRO oferă acum resurse pentru întâlniri: +3.000 de diapozitive și webcast-uri; rezumate și ePostere.
Daily ReporterDatopotamab deruxtecan reached the PFS endpoint for previously treated NSCLC23 Oct 2023TROP2-directed ADC increased PFS and reduced toxicity in comparison with chemotherapy, but the results of TROPION Lung01 are not practice changing.
TROP2-directed ADC increased PFS and reduced toxicity in comparison with chemotherapy, but the results of TROPION Lung01 are not practice changing.
Daily Reporter177Lu PSMA-617 îmbunătățește rPFS pentru pacienții cu cancer de prostată rezistenți la castrare metastatic, care sunt naivi la taxani23 oct 2023Descoperirile studiului PSMAfore sunt limitate de faptul că nu prezintă un beneficiu în ceea ce privește OS.